

CLAIMS:

1. Use of lurbinectedin in the manufacture of a medicament for the treatment of a solid tumour, wherein said ~~treatment~~medicament ~~comprises~~is to be administered as a combination therapy of lurbinectedin and with an immune checkpoint inhibitor to a patient in need thereof.

2. Use of an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said ~~treatment~~medicament is to be administered as a combination therapy of lurbinectedin and with an immune checkpoint inhibitor to a patient in need thereof.

3. Use of lurbinectedin and an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said ~~treatment~~medicament is to be ~~comprises~~administered as a combination therapy of lurbinectedin and with an immune checkpoint inhibitor to a patient in need thereof.

4. A method of treatment of a solid tumour, the method comprising administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof, thereby treating the solid tumour.

24. The ~~method of claim 1~~use of any one of the preceding claims, wherein the immune checkpoint inhibitor comprises an immunoglobulin molecule, preferably an antibody, targeting an immune checkpoint molecule.

35. The ~~use of any one of the preceding claims~~method of claim 2, wherein the immune checkpoint molecule is selected from CTLA-4, PD-1, and PD-L1.

46. The ~~method of use of~~ any one of the preceding claims, wherein the immune checkpoint inhibitor comprises a plurality of inhibitors targeting a plurality of immune checkpoint molecules, preferably CTLA-4 and PD-1.

57. The ~~method of use of~~ any one of the preceding claims wherein the immune checkpoint inhibitor comprises a monoclonal antibody which specifically binds CTLA-4, or which specifically binds PD-1, or which specifically binds PD-L1.

68. The ~~use method of claim 5-7~~ wherein the monoclonal antibody is selected from pembrolizumab, nivolumab, ipilimumab, avelumab, atezolizumab, durvalumab, cemiplimab (REGN2810), camrelizumab (SHR1210), envafolimab (KN035), sintilimab

(IBI308), spartalizumab (PDR001), tislelizumab (BGB-A317), prolgolimab (BCD-100), toripalimab (JS001), dostarlimab (TSR-042, WBP-285) and tremelimumab (ticilimumab, CP-675,206).

5 9. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is atezolizumab.

10. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is avelumab.

11. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is pembrolizumab.

10 12. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is nivolumab.

13. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is ipilimumab.

15 14. The use of any one of the preceding claims, wherein the immune checkpoint inhibitor is dostarlimab.

~~715. The use of any one of the preceding claims, method of any preceding claim wherein the lurbinectedin and the immune checkpoint inhibitor are administered concurrently, separately or sequentially.~~

20 ~~816. The method-use of claim 7-15 wherein the lurbinectedin is administered initially, followed by the immune checkpoint inhibitor.~~

~~917. The use of any one of the preceding claims, method of any preceding claim wherein multiple administrations of either the lurbinectedin, or the immune checkpoint inhibitor, or both, are given.~~

25 ~~4018. The use of any one of the preceding claims, method of any preceding claim, wherein lurbinectedin is administered by intravenous infusion.~~

~~4419. The use of any one of the preceding claims, method of any preceding claim, wherein the immune checkpoint inhibitor is administered by intravenous infusion.~~

~~4220. The use of any one of the preceding claims, method of any preceding claim wherein the solid tumour is selected from the group consisting of prostate cancer,~~

breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer, and sarcomas.

5 4321. The use of any one of the preceding claims, ~~method of any preceding claim~~, wherein the solid tumour is a lung cancer, melanoma, or is breast cancer.

4422. The use of any one of the preceding claims, ~~method of any preceding claim~~, wherein the solid tumour expresses PD-L1.

10 4523. The use of any one of the preceding claims, ~~method of any preceding claim~~, wherein the method further comprises determining whether the tumour to be treated expresses PD-L1 prior to beginning treatment.

4624. The use of any one of the preceding claims, ~~method of any preceding claim~~, wherein the treatment results in one or more of: reduction in tumour size; delay in growth of tumour; prolongation of life of the patient; delay in disease progression; remission.

15 4725. The use of any one of the preceding claims, wherein the treatment comprises ~~A method of prolonging survival of a patient having a solid tumour, the method comprising administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof, thereby prolonging survival of the patient.~~

20 4826. The use of any one of the preceding claims, wherein the treatment comprises ~~A method of delaying disease progression of a solid tumour in a patient, the method comprising administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof, thereby delaying disease progression of the solid tumour.~~

25 4927. The use of any one of the preceding claims, wherein the treatment comprises ~~A method of reducing or delaying growth of a solid tumour, the method comprising administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof, thereby reducing or delaying growth of the solid tumour.~~

30 2028. A method of selecting a patient having a solid tumour for combination therapy, the method comprising determining *in vitro* whether the solid tumour expresses PD-L1, and if so, selecting the patient for combination therapy wherein the combination

therapy comprises administering is to be administered as a combination therapy of lurbinectedin and an immune checkpoint inhibitor.

~~2129.~~ The method of claim ~~2028~~, further comprising providing said combination therapy to the patient.

5 ~~22.~~ Use of lurbinectedin in the manufacture of a medicament for the treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

10 ~~23.~~ Use of an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

15 ~~24.~~ Use of lurbinectedin and an immune checkpoint inhibitor in the manufacture of a medicament for the treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

~~25.~~ Lurbinectedin for use in a method of treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

20 ~~26.~~ An immune checkpoint inhibitor for use in a method of treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

25 ~~27.~~ Lurbinectedin and an immune checkpoint inhibitor for use in a method of treatment of a solid tumour, wherein said treatment comprises administering a combination therapy of lurbinectedin and an immune checkpoint inhibitor to a patient in need thereof.

~~283029.~~ A pharmaceutical package comprising lurbinectedin and an immune checkpoint inhibitor.

3130. A pharmaceutical package comprising lurbinectedin, together with instructions for administration in combination with an immune checkpoint inhibitor.

3231. A pharmaceutical package comprising an immune checkpoint inhibitor, together with instructions for administration in combination with lurbinectedin.